secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-032281
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q3 net loss $14.3M; EsoGuard test volume up 436% YoY to 1,088
-------------------------------------------------------------------------------

- GAAP net loss attributable to common stockholders $14.3M (-$0.39/share); non-GAAP adjusted loss $10.2M (-$0.28/share).
- EsoGuard test volume 1,088 in Q3 (+28% sequential, +436% YoY); EsoGuard-related revenue $0.1M.
- Cash and equivalents $26.9M at Sep 30, 2022, down from $53.7M at Dec 31, 2021; committed equity facility up to $50M.
- Sales team at 37, target 58 early 2023. 13 Lucid Test Centers in 11 states; 3 more by year-end.
- EsoCheck production moved to Coastline International; expects 60% reduction in per-unit manufacturing cost.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/0001493152-22-032281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315222032281/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer